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Abstract
Tacrolimus  is  a  macrolide  immunosuppressant  that  is  structurally  similar  to
rapamycin  and  has  been  found  to  have  potent  immunosuppressive  properties,
showing  10-  to  100-fold  higher  potency  for  inhibiting  lymphocyte  activation  than
cyclosporine  A  (CsA).  Because  less  variability  in  absorption  and  serum  levels  is
observed among patients treated with tacrolimus compared with those who receive
oral CsA, tacrolimus has been suggested to be more easily and safely administered
to patients with refractory ulcerative colitis (UC) than CsA. However, because oral
tacrolimus has  a  slower  onset  of  action than intravenous  CsA and food intake  is
known to reduce tacrolimus serum trough levels due to its low absorption rate, the
proper  method  for  administration  of  oral  tacrolimus  has  not  been  determined.
Moreover, the long-term effects of oral tacrolimus also remain unclear. In this chapter,
key issues regarding the use of oral tacrolimus in patients with UC are reviewed.
Keywords: ulcerative colitis, refractory disease, accelerated step-up, cyclosporine A,
top-down therapy
1. Introduction
Tacrolimus, also known as the macrolide immunosuppressant FK506 (formerly FR900506), is
a powerful and selective anti-T-lymphocyte agent discovered in 1984. The first letter “T”
represents Tsukuba, Japan, where tacrolimus was first identified. Because tacrolimus is a
macrolide, the letters “ACROL” are included after the initial T. Finally, the letters “IMUS”
represent the immunosuppressive effects of the drug [1]. Tacrolimus was isolated from the
fermentation broth of the fungus Streptomyces tsukubaensis, which was isolated from a soil
sample in Tsukuba, Ibaraki Prefecture, Japan [2].
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The molecular structure of tacrolimus is completely different from that of cyclosporine A
(CsA). However, their immunosuppressive properties are remarkably similar [2–5]. Initial
reports showed that tacrolimus acts as an immunosuppressant by inhibiting interleukin 2
(IL-2) production and blocking the response of mixed lymphocyte culture at concentrations
100 times lower than that of CsA [5]. Early multicenter trials were conducted to evaluate the
safety and efficacy of tacrolimus in patients who underwent liver transplantation; these trials
showed that the effects of tacrolimus were equivalent to those of CsA-based immunosuppres-
sive regimens [1, 6, 7]. Thus, clinically, tacrolimus was initially developed as a drug for the
prevention and/or treatment of graft rejection in organ transplantation patients [8, 9].
Regarding the inflammatory bowel disease (IBD), tacrolimus has been used to treat fistulizing
Crohn’s disease (CD) and refractory ulcerative colitis (UC) [10]. Because topical administration
of tacrolimus can result in high concentrations in the tissue and can effectively regulate the
local immune response, topical tacrolimus has also been used to treat refractory distal colitis
and extraintestinal UC, such as pyoderma gangrenosum [11–13]. Moreover, tacrolimus has a
rapid onset of action and is highly effective in patients with refractory UC; therefore, tacrolimus
is approved as an alternative treatment option for refractory UC under the national health
insurance system in Japan [14]. The physicochemical properties of tacrolimus result in large
variations in oral absorption and metabolism for clearance from the body [9]. Moreover, the
therapeutic window of tacrolimus is narrow. Thus, therapeutic drug monitoring is necessary.
2. Clinical pharmacokinetics
Tacrolimus is highly lipophilic and is excreted from the body after undergoing extensive
metabolism [9]. Food intake is known to reduce serum level of tacrolimus resulting from its
low absorption rate [14]. After absorption, tacrolimus is metabolized by the liver and small
intestinal microsomes containing cytochrome P-450 3A4 and 3A5, which are responsible for
the biotransformation of tacrolimus [9]. After being metabolized, tacrolimus is mainly excreted
in the feces and bile as conjugates. Using 14C-labeled tacrolimus, Iwasaki et al. reported that
urinary excretion accounts for less than 3% of the total dose administered and that less than
0.5% of the unaltered drug is detectable in feces and urine in health human subjects [15].
Because ketoconazole, fluconazole, erythromycin, diltiazem, cimetidine, methylprednisolone,
and CsA are also metabolized by cytochrome P-450, tacrolimus should be used with caution
in patients receiving these drugs [16]. On the other hand, coadministration of rifampicin
significantly increases tacrolimus clearance; indeed, rifampicin treatment causes decreased
levels of tacrolimus in the blood [17]. Because genetic polymorphisms are known to exist in
cytochrome P-450 3A4 and 3A5, the determination of cytochrome P-450 3A genotypes in
patients with refractory UC may provide useful information for selecting the optimal dosage
of tacrolimus [9]. In patients with UC, Hirai et al. analyzed the association of cytochrome P-450
3A5 genetic polymorphisms with tacrolimus pharmacokinetics and efficacy in Japanese
patients with UC. Their results showed that the trough level of tacrolimus is significantly
higher in cytochrome P-450 3A5-nonexpressing (*3*3) patients than in cytochrome P-450 3A5-
expressing (*1*3 and *1*1) patients and that the short-term remission rate is significantly
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different among these patient groups [18]. Additionally, lack of food intake and silencing of
cytochrome P-450 3A5 are associated with achievement of optimal trough levels on multivari-
ate analysis. The proton pump inhibitor lansoprazole is also metabolized by cytochrome P-450
3A4 and elevates the blood concentration of tacrolimus. Therefore, when lansoprazole is
coadministered with tacrolimus, repeated therapeutic drug monitoring is needed to prevent
the incidence of adverse events [19]. Because tacrolimus is also a substrate of P-glycoprotein,
polymorphisms in P-glycoprotein may also determine tacrolimus response in patients with
UC [20]. Elevated intestinal P-glycoprotein decreases tacrolimus absorption, thereby leading
to decreased blood concentrations and decreased efficacy in patients treated with tacrolimus
[21].
3. Immunosuppressive effects
Calcineurin inhibitors, such as CsA and tacrolimus, block the production of IL-2 and the
activation of T lymphocytes [22]. CsA and tacrolimus belong to the family of immunophilin-
binding drugs, and the drug-immunophilin complex inhibits calcineurin, preventing dephos-
phorylation of nuclear factor of activated T cells (NFAT) and resulting in decreased expression
of cytokines, such as IL-2 [5, 8, 23, 24] (Figure 1). Although their immunosuppressive properties
are similar, tacrolimus has been found to show 10- to 100-fold more potent inhibition of
lymphocyte activation than CsA [5]. Additionally, tacrolimus acts on other pathways, includ-
ing blockade of cytokine receptor expression and cytokine effects on target cells [25]. Interest-
ingly, CsA, but not tacrolimus, suppresses nitric oxidase production, contributing to the side
effects of hypertension and nephrotoxicity and enabling long-term use of CsA [26]. On the
other hand, tacrolimus is known to be associated with many adverse effects, including
hypertension and renal dysfunction [27].
Figure 1. Calcineurin inhibitors in T cells. CsA and tacrolimus bind to immunophilin. The drug-immunophilin com-
plexes inhibit calcineurin, preventing dephosphorylation of NFAT and resulting in decrease expression of cytokines,
such as IL-2.
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4. Tacrolimus in the treatment of refractory UC
UC is an idiopathic IBD characterized by a chronic relapsing/intermittent clinical course.
Aminosalicylates are typically used as first-line treatment for patients with UC, while steroids
are usually considered a second-line treatment and are used to induce remission when
remission cannot be achieved with aminosalicylates [28]. Because steroids have a rapid onset
of action and are highly effective, they are reserved for treatment in patients with severe UC
who fail to respond to primary therapy. However, these agents are associated with considerable
systemic adverse effects [29]. Nevertheless, approximately 20 % of patients with UC have
chronically active disease that requires several courses of steroids [30]. As a result, many
patients with refractory UC (e.g., steroid-refractory or steroid-dependent UC) experience
severe complications associated with steroid treatment before stable remission can be ach-
ieved, and many of these patients ultimately require colectomy [30, 31].
Oral tacrolimus began to be used as an alternative treatment option for refractory UC in July
2009 under the national health insurance system in Japan [14]. Because tacrolimus does not
depend on mucosal integrity for absorption, less variability in absorption and serum level is
observed among patients treated with tacrolimus compared with those who received oral CsA
[32]. Thus, oral tacrolimus has been suggested to be more easily and safely administered to
patients with refractory UC than CsA. A study published by Ogata et al. was the first random-
ized controlled trial to demonstrate the efficacy of oral tacrolimus in refractory UC [33].
Importantly, they also confirmed that tacrolimus showed efficacy in a trough concentration-
dependent manner. In their study, patients with refractory UC were randomly assigned to a
high trough concentration (10–15 ng/mL) group, low trough concentration (5–10 ng/mL)
group, or placebo group. A total of 68.4% of patients in the high trough concentration group
improved within 2 weeks after administration of tacrolimus, whereas only 38.1% of patients
in the low trough concentration group experienced disease improvement. To date, several
uncontrolled and placebo-controlled studies have demonstrated that tacrolimus can induce
remission in both adults and children, and these reports suggested that tacrolimus had a
dramatic concentration-dependent effect, with the optimal target range appearing to be 10–
15 ng/mL with a relatively short period of efficacy [34–38].
Nonetheless, we have still occasionally experienced patients who did not demonstrate
improvement even though the appropriate trough level was achieved with oral tacrolimus
using standard dosing (an initial dose of 0.025 mg/kg daily is approved under the national
health insurance in Japan). We previously examined the short-term efficacy of tacrolimus in
refractory UC and found that the clinical response rate at 4 weeks after the initiation of
tacrolimus treatment correlated with the mean trough level at 8–21 days after treatment and
that the primitive trough level was increased within 5 days after administration, which was
important for obtaining the appropriate trough level at 8 days after tacrolimus administration
[39]. Even when the starting dose of tacrolimus was set to 0.1 mg/kg/day to obtain early
achievement of the appropriate trough level, more than 7 days was required to achieve the
target tacrolimus blood concentration because food intake is known to reduce serum levels of
tacrolimus by slowing the absorption rate [40]. Therefore, we conducted a prospective,
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multicenter, observational study to evaluate the efficacy and safety of rapid induction therapy
with oral tacrolimus, starting at 0.1 mg/kg/day without a meal, in patients with steroid-
refractory UC [41]. The dose was adjusted to maintain trough levels of 10–15 ng/mL for the
first 2 weeks. Beginning at 2 weeks after the initiation of tacrolimus therapy, the tacrolimus
trough concentration was gradually maintained at a lower level of 5–10 ng/mL. From this
analysis, 0.15–0.16 mg/kg/day oral tacrolimus was needed to achieve the appropriate trough
level; the mean trough level reached a peak on day 2, and 93.5% of patients could maintain
high trough levels for the first 7 days of treatment. After 2 weeks, 73.1% of patients with
refractory UC experienced clinical responses, and 75.4% of patients achieved clinical remission
at 4 weeks after tacrolimus initiation.
Regarding the long-term efficacy in patients with refractory UC, Yamamoto et al. investigat-
ed the efficacy of tacrolimus as maintenance therapy for patients with refractory UC and
reported that the cumulative colectomy-free survival rate was 62% at 65 months. They also
reported that the colectomy-free survival rate was significantly higher in patients who re-
sponded to tacrolimus within 30 days than in those who did not and suggested that tacroli-
mus should be administered to achieve a low trough level (5–10 ng/mL) as maintenance
therapy in patients with UC [42].
Currently, antitumor necrosis factor alpha (anti-TNFα) antibodies, such as infliximab and
adalimumab, are also used as a treatment option for patients with refractory UC [43, 44].
Because there is no need to adjust the drug concentration when treating patients with these
biologics and because they can be used for both induction and maintenance of remission in
UC, such treatments have been widely used in the case of refractory UC. However, to date,
there are very few reports comparing the efficacy of tacrolimus and anti-TNFα antibodies for
refractory UC. Recently, Yamamoto et al. retrospectively compared the short-term safety and
efficacy of tacrolimus versus anti-TNFα antibodies (infliximab or adalimumab) for moderate-
to-severe active UC and reported that the response rate was higher in patients treated with
tacrolimus, although no significant difference was observed [45].
Patients with refractory UC who failed second-line therapies with cyclosporine, tacrolimus, or
infliximab have limited medical options to achieve remission and avoid colectomy. To date,
several studies have evaluated the efficacy of infliximab as rescue therapy in patients who were
refractory to tacrolimus and reported that the short-term response rates ranged from 25.0 to
75.0% [46–49]. Administration of infliximab in patients with refractory UC who did not
respond to tacrolimus may be useful for induction remission and could help to avoid the need
for colectomy. However, it is still unclear which sequential therapeutic strategies (tacrolimus
switching to infliximab or infliximab switching to tacrolimus) should be used.
5. Top-down or accelerated step-up therapy with oral tacrolimus
In patients with CD, top-down therapy involves early introduction of biologics and/or
immunomodulators in patients with newly diagnosed disease. With regard to UC, top-down
therapy may not be suitable for all patients. Recently, studies have examined the use of
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“accelerated step-up therapy,” which involves a “step-up” aggressive treatment algorithm that
preserves the concept of matching severity to treatment potency yet recognizes the potential
benefits of the earlier use of biologics and/or immunomodulators [50]. For many patients with
UC, such an accelerated step-up approach may be the best strategy [51]. Because differences
in the onset of action of various agents are thought to influence the achievement and mainte-
nance of disease remission, early intervention with tacrolimus may improve the long-term
prognosis of patients with UC, similar to the effects of infliximab in patients with CD. There-
fore, we evaluated the efficacy of oral tacrolimus in patients with moderate-to-severe UC not
receiving concomitant steroid therapy. The results showed that early intervention with
tacrolimus was highly effective at inducing remission (72.7% at 4 weeks and 90.0% at 12 weeks)
and maintenance remission (72.5% at a mean follow-up of 10.4 months) [52]. Although
additional studies are required to establish the efficacy and safety of oral tacrolimus therapy
in patients with UC, oral tacrolimus may represent a top-down or accelerated step-up
treatment option for patients with moderate-to-severe UC (Figure 2).
Figure 2. Treatment options for patients with moderate/severe UC. Because prompt intervention with potent medical
therapy is crucial in the management of severe UC, top-down therapy with tacrolimus may be useful for avoiding ste-
roid dependency and improving prognosis (*). Recognizing the potential benefits of the earlier use of immunomodula-
tors/biologics and accelerating the introduction of these drugs are defined as “accelerated step-up therapy,” thereby
avoiding therapies that have minimal efficacy (**).
6. Impact of tacrolimus on cytomegalovirus (CMV) colitis
CMV infection has been reported to be a cause of refractory UC. Because the specific endo-
scopic features of refractory UC associated with CMV infection have not been clearly descri-
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bed, diagnosing CMV infection at an early stage is difficult [53]. Although quantitative real-
time polymerase chain reaction (qPCR) for detecting CMV infection in colonic mucosa has
been shown to exhibit high sensitivity, the appropriate therapeutic approach for patients with
UC having CMV-DNA-positive colonic mucosa remains unclear. In a randomized trial
comparing tacrolimus and CsA for prevention of liver allograft rejection, the incidence of CMV
infection was found to be significantly lower in patients receiving tacrolimus (15.7 and 25.0%
for tacrolimus and CsA, respectively) [7]. Alessiani et al. also reported that tacrolimus
treatment in liver transplant recipients resulted in a significantly lower incidence of sympto-
matic CMV infection compared with that observed after CsA treatment [54]. Shiraki et al.
showed the suppressive effects of tacrolimus on CMV replication in vitro [55]. In contrast to
tacrolimus, CsA has been reported to enhance the replication of CMV [55]. We used qPCR to
identify patients with UC having CMV infection and assessed the outcomes of patients with
CMV infections [56]. Our results showed that all CMV-DNA-positive patients who were
treated with oral tacrolimus without ganciclovir showed clinical responses and decreased
numbers of CMV-DNA copies (Figure 3). Because the use of steroids is known to increase the
risk of CMV infection, which is associated with disease exacerbation and refractoriness, oral
tacrolimus should be used prior to steroid therapy in patients with severe or refractory UC [57].
Figure 3. All CMV-DNA-positive patients who were treated with oral tacrolimus showed clinical responses and de-
creased numbers of CMV-DNA copies without concomitant ganciclovir [56].
7. Adverse effects
Similar to CsA, tacrolimus is known to be associated with many adverse effects, such as
infections, renal dysfunction, hypertension, hyperglycemia, and neurological toxicity. How-
ever, these effects are generally mild and reversible. Although nephrotoxicity may be a limiting
factor for the long-term use of tacrolimus, mean serum creatinine was not significantly elevated
following short-term use of tacrolimus. With respect to blood glucose levels, Benson et al.
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reported that 62.5% of patients with UC had elevated glucose levels; most of these patients
were on corticosteroid therapy at the time [35]. Interestingly, because tacrolimus treatment has
strong effects on steroid sparing, the mean fasting blood glucose level was reported to be
significantly decreased after the initiation of tacrolimus treatment in patients with refractory
UC [41]. During tacrolimus treatment, many patients develop hypomagnesemia (33.3–87.5 %)
[33, 35, 41]. Additionally, other adverse effects, such as tremor, nausea, and headache, are often
experienced. However, patients rarely have to discontinue tacrolimus therapy due to these
adverse effects. Thus, induction therapy with tacrolimus is safe and well tolerated in patients
with UC.
8. Conclusions
Tacrolimus is a potent immunosuppressive agent that is useful for inducing remission of
refractory UC. Although the long-term efficacy and safety of tacrolimus in patients with UC
have not been clearly elucidated, induction therapy with tacrolimus is safe and well tolerated
in patients with refractory UC. Because of the requirement for tacrolimus dose adjustment and
large variations in the oral absorption and metabolism of tacrolimus, physicians have to know
the pharmacokinetics of tacrolimus to obtain maximum efficacy. Rapid induction therapy with
oral tacrolimus in the early phase of treatment may provide excellent clinical outcomes and
avoid the need for surgery for refractory UC. Therefore, oral tacrolimus may represent a top-
down or accelerated step-up treatment option in cases of severe/extensive UC. However, thus
far, tacrolimus is used primarily in Japan, and this drug is still not available in some other
countries for the treatment of patients with UC because there are only two randomized
controlled trials [33, 58] and a small number of studies confirming the efficacy and safety of
tacrolimus. Further controlled studies with large numbers of patients are needed.
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